FDA Peptide Reclassification 2026: What Moved to Category 1

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides on the FDA’s Category 2 restricted list would be reclassified back to Category 1 — restoring legal access through compounding pharmacies with a physician’s prescription [1].

This is the most significant regulatory shift in peptide therapy since the original restrictions were imposed in late 2023. For patients, clinicians, and compounding pharmacies, it changes the calculus on how peptides can be legally obtained and prescribed.

Here’s exactly what happened, which peptides are affected, and what it means for you. For the broader picture on whether peptides are legal, start with our pillar guide.

Key Takeaways

14 of 19 restricted peptides are expected to return to Category 1 (legal for compounding)
BPC-157, Thymosin Alpha-1, TB-500, CJC-1295, Ipamorelin, and others are included
About 5 peptides — including Melanotan II — are expected to remain restricted
You still need a prescription; this is not over-the-counter access
The FDA’s formal updated list is expected within weeks of the announcement
Grey-market “research” peptides remain unregulated regardless of this change

Background: The 2023-2024 Peptide Restrictions
What Happened on February 27, 2026
Category 1 vs. Category 2: What These Mean
The 14 Peptides Returning to Category 1
The 5 Peptides Expected to Stay Restricted
What This Means for Patients
What This Means for Compounding Pharmacies
The Grey Market Problem
Timeline and Next Steps
FAQ

Background: The 2023-2024 Peptide Restrictions

Between late 2023 and December 2024, the FDA placed 19 peptides on its Category 2 list for 503A bulk drug substances. Category 2 status means the FDA considers these compounds to present “potential significant safety risks,” and compounding pharmacies are prohibited from using them to prepare patient medications.

The 19 peptides included some of the most widely prescribed compounds in regenerative and anti-aging medicine. Millions of patients had been receiving these therapies under physician supervision — in some cases for years — when access was cut off.

The FDA cited two primary concerns: insufficient large-scale human clinical trial data and potential immunogenicity (the risk of triggering immune reactions). But many clinicians and pharmacy groups pushed back hard. A coalition of compounding pharmacies filed a legal challenge arguing the FDA had not identified specific safety signals to justify the restrictions and had bypassed required procedural steps [2].

Several members of Congress weighed in publicly, questioning whether the FDA’s action was proportionate to actual risk. The debate centered on a core tension: these peptides lacked full FDA approval, but they also lacked evidence of serious harm when used under medical supervision.

For a broader overview of peptide legality, see our complete guide on whether peptides are legal.

What Happened on February 27, 2026

During an appearance on the Joe Rogan Experience podcast (Episode #2461), HHS Secretary Kennedy announced that approximately 14 of the 19 restricted peptides would be moved from Category 2 back to Category 1 [1].

Kennedy stated that the original restrictions were imposed “without legitimate safety signals” and that the FDA’s action had the opposite of its intended effect — it “created the grey market” by pushing patients toward unregulated sources with no quality control, no accurate dosing, and no physician oversight.

He framed the reclassification as ensuring Americans get “a good product from ethical suppliers” rather than “substandard product” from unregulated vendors.

The announcement did not include a formal FDA publication. The updated list is expected within weeks. Some compounding pharmacies have already begun preparing to resume production, though most are waiting for the official guidance before filling prescriptions.

Category 1 vs. Category 2: What These Mean

These categories are part of the FDA’s framework for regulating which substances compounding pharmacies can use. They’re separate from — and much less rigorous than — full FDA drug approval.

Category 1

Substances that compounding pharmacies may use while under ongoing evaluation
Licensed 503A pharmacies (state-regulated, individual prescriptions) and 503B outsourcing facilities (FDA-registered, batch compounding) can prepare medications using these substances
A valid prescription from a licensed provider is required

Category 2

Substances the FDA has identified as presenting potential significant safety risks
Compounding pharmacies cannot use these substances
Effectively a ban on compounded preparations of these compounds

What Neither Category Means

Not FDA approval. Category 1 peptides have not been through clinical trials for safety and efficacy. They are compounded preparations, not approved drugs.
Not over-the-counter. You cannot walk into a pharmacy and buy them without a prescription.
Not an insurance event. Most insurers do not cover compounded peptides regardless of their category status.

The 503A vs. 503B pharmacy distinction adds another layer. Both types can use Category 1 substances, but they operate under different regulatory frameworks and oversight levels.

The 14 Peptides Returning to Category 1

Based on the announcement and analysis from regulatory experts, these are the peptides expected to return to legal compounding status. The formal FDA list will confirm the exact roster.

Tissue Repair and Recovery

BPC-157 (Body Protection Compound-157)

The most in-demand peptide on the restricted list. BPC-157 is derived from a protein found in human gastric juice. Animal studies show broad effects on tissue repair, including tendons, ligaments, muscle, gut lining, and bone [3]. Human clinical trial data is limited, but clinical experience from practitioners has been extensive.

BPC-157 was one of the most prescribed peptides before the ban, used widely for gut healing, joint pain, musculoskeletal recovery, and post-surgical healing. Its return to Category 1 is arguably the single most impactful change in the reclassification. For full details on the compound, see our BPC-157 guide.

Thymosin Beta-4 Fragment (TB-500)

A naturally occurring peptide involved in tissue repair, wound healing, and reducing inflammation. Studied for cardiac tissue repair, corneal healing, and musculoskeletal recovery. Often used alongside BPC-157 in the Wolverine peptide stack.

Immune Support

Thymosin Alpha-1

One of the most well-evidenced peptides on this entire list. Thymosin Alpha-1 is approved as a pharmaceutical product in over 30 countries for hepatitis B, hepatitis C, and as an immune adjuvant in cancer treatment [4]. Its placement on Category 2 was particularly controversial given its established international safety record.

KPV (Lys-Pro-Val)

A tripeptide fragment of alpha-MSH with anti-inflammatory properties. Studied in inflammatory bowel conditions and broader immune modulation. Sometimes used alongside BPC-157 for gut health protocols.

Metabolic Health

AOD-9604

A modified fragment of human growth hormone targeting fat metabolism without the broader hormonal effects of full HGH. AOD-9604 went through Phase II clinical trials as an anti-obesity treatment, giving it a stronger safety profile than many peptides on this list [5]. Commonly used in fat loss protocols.

MOTS-C

A mitochondrial-derived peptide involved in metabolic regulation, insulin sensitivity, and exercise physiology. Early research suggests roles in glucose metabolism and physical endurance [6]. Growing interest in its potential for metabolic syndrome.

Growth Hormone Release

CJC-1295

A growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary to release growth hormone. Often combined with Ipamorelin in what has become the most popular GH-support stack. Used for sleep quality, muscle growth, body composition, and recovery.

Ipamorelin

A selective growth hormone secretagogue considered one of the mildest GHRPs available. Ipamorelin stimulates GH release without significantly affecting cortisol or prolactin, giving it a favorable side effect profile compared to older GHRPs.

GHRP-2 and GHRP-6

Earlier-generation growth hormone-releasing peptides. More potent GH stimulation than Ipamorelin but with more pronounced hunger effects (especially GHRP-6) and broader hormonal impact. Still used in specific peptide protocols where stronger GH stimulation is needed.

Cognitive and Neurological

Semax

A synthetic analog of ACTH(4-10) studied for cognitive enhancement, neuroprotection, and stroke recovery. Approved in Russia as a prescription drug. Studied for attention, memory, and neurological rehabilitation [7].

Selank

A synthetic peptide derived from tuftsin with anxiolytic and immunomodulatory properties. Also approved in Russia. Studied for generalized anxiety, cognitive function, and immune regulation.

Anti-Aging and Longevity

GHK-Cu

A naturally occurring copper peptide that declines with age. Studied for wound healing, skin regeneration, hair growth, and anti-inflammatory effects. Used topically and as an injectable in anti-aging and skin protocols.

Epitalon

A synthetic tetrapeptide studied for its effects on telomerase activation and melatonin regulation. Research is more limited than other peptides on this list, but interest in its longevity applications has grown significantly.

The 5 Peptides Expected to Stay Restricted

Not all 19 peptides are coming back. Approximately 5 are expected to remain on Category 2 due to weaker safety profiles or more significant risk concerns:

Melanotan II — Associated with cardiovascular side effects and potential melanoma risk. Widely used for tanning and sexual dysfunction, but the safety concerns are considered more substantial than other peptides on the list.

Cathelicidin LL-37 — An antimicrobial peptide with very limited human safety data in the compounded injectable form.

PEG-MGF (Pegylated Mechano Growth Factor) — A pegylated growth factor derivative with insufficient safety evidence for compounded use.

Emideltide (DSIP / Delta Sleep-Inducing Peptide) — Limited safety data for human use despite its theoretical appeal for sleep regulation.

Kisspeptin-10 — A hormone-regulating peptide with concerns about unpredictable effects on the reproductive endocrine axis.

The final determination will come with the FDA’s published update. Some analysts suggest the exact number could shift slightly — the “approximately 14” language from Kennedy’s announcement leaves room for adjustment.

What This Means for Patients

If You Were Using Peptides Before the Ban

The reclassification means you can likely resume your previous protocol through a licensed provider. Your physician can prescribe Category 1 peptides, and a compounding pharmacy can fill them. The process works the same as before 2023.

If you switched to grey-market “research” peptides during the ban, this is your opportunity to return to regulated, quality-controlled products with proper medical oversight.

If You’re New to Peptide Therapy

The reclassification opens the door to physician-supervised peptide therapy through legitimate channels. The steps:

Consult with a provider experienced in peptide therapy — either in person or via telehealth
Get a clinical evaluation and prescription
Fill at a licensed compounding pharmacy
Follow your protocol with ongoing monitoring

For guidance on getting started, see how to get peptides prescribed and whether you need a prescription.

Cost Expectations

Compounded peptides typically cost $150-400 per month depending on the specific peptide, dosage, and pharmacy. This is almost always out-of-pocket — insurance coverage for compounded peptides remains rare. Our peptide therapy cost guide has detailed pricing breakdowns.

What This Means for Compounding Pharmacies

503A and 503B pharmacies that previously compounded these peptides can resume once the formal FDA guidance is published. Key requirements remain:

Valid prescription from a licensed provider for each patient (503A) or compliance with 503B batch requirements
USP 795 and 797 standards for compounding and sterility
Sourcing bulk drug substances from qualified suppliers with certificates of analysis
Proper stability testing and beyond-use dating

Pharmacies are expected to ramp up production quickly given pent-up demand. Supply constraints may cause short-term delays or pricing fluctuations in the weeks after the official list is published.

The Grey Market Problem

The Category 2 restrictions didn’t eliminate demand for peptides. They redirected it toward unregulated channels.

Between 2024 and early 2026, the “research use only” peptide market exploded. Vendors sold peptides labeled as research chemicals, sidestepping FDA compounding regulations. Buyers — overwhelmingly using them for personal health, not laboratory research — had no way to verify purity, sterility, or accurate dosing.

A December 2025 investigation found widespread contamination and mislabeling among grey-market products [8]. Some contained less peptide than advertised. Others contained impurities that wouldn’t be present in pharmacy-compounded preparations.

The enforcement crackdown accelerated in early 2026. Peptide Sciences, one of the largest research peptide vendors, voluntarily shut down in March 2026 [9]. Other vendors have faced increased scrutiny.

The reclassification undercuts the grey market’s core value proposition. When patients can get pharmaceutical-grade peptides from licensed pharmacies with a prescription, the risk-reward calculation of buying unregulated “research” products shifts dramatically.

For more on the distinction, see our guides on grey market vs. prescription peptides and whether research peptides are safe.

Timeline and Next Steps

Here’s what we know about the rollout:

February 27, 2026: HHS Secretary Kennedy announces reclassification on Joe Rogan Experience
March 2026 (expected): FDA publishes formal updated Category 1 and Category 2 lists
Weeks following publication: Compounding pharmacies begin filling prescriptions for reclassified peptides
Ongoing: FDA continues evaluating remaining Category 2 substances; PCAC (Pharmacy Compounding Advisory Committee) process for future additions

We’ll update this page as the FDA publishes its formal guidance. The core announcement is confirmed — the remaining question is exactly which peptides make the final list and the precise timeline for pharmacies to begin compounding.

FAQ

When will the reclassified peptides actually be available?▼

The FDA’s formal updated list is expected within weeks of the February 27 announcement. Once published, compounding pharmacies can begin filling prescriptions immediately — though it may take a few additional weeks for supply chains to fully ramp up. Some pharmacies had already begun sourcing bulk substances in anticipation.

Is BPC-157 legal again?▼

Yes — or more precisely, it’s expected to be. BPC-157 is among the 14 peptides announced for reclassification to Category 1. Once the formal FDA guidance is published, licensed compounding pharmacies can legally prepare it with a physician’s prescription. For details on this peptide specifically, see our BPC-157 guide and BPC-157 FDA status page.

Do I still need a prescription for peptides?▼

Yes. Category 1 status means compounding pharmacies can prepare these peptides — but only with a valid prescription from a licensed healthcare provider. Nothing about the reclassification changes the prescription requirement. See how to get peptides prescribed and can telehealth prescribe peptides.

Are “research peptides” from online vendors now legal?▼

No. The reclassification applies specifically to compounding pharmacy regulations. It has no direct effect on the legal status of “research use only” peptides sold by unregulated vendors. Those products exist in a separate regulatory space and carry significant quality and safety risks. The reclassification actually makes grey-market purchases harder to justify, since legal alternatives are now available.

Why did the FDA reverse course?▼

The reclassification followed a legal challenge from compounding pharmacies arguing the FDA lacked the required safety signal to justify Category 2 placement. The incoming HHS leadership under Secretary Kennedy was also philosophically aligned with expanding access to these therapies. Kennedy stated the original restrictions were made “without legitimate safety signals” and had pushed patients toward more dangerous unregulated products.

Sources

Joe Rogan Experience #2461 with Robert F. Kennedy Jr. February 27, 2026. Spotify/YouTube.
Frier Levitt, LLC. “Regulatory Status of Peptide Compounding in 2025.” frierlevitt.com. Accessed March 2026.
Sikiric P, et al. “Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract.” Current Pharmaceutical Design. 2011;17(16):1612-1632.
Tuthill C, et al. “Thymalfasin: Biological properties and clinical applications.” International Immunopharmacology. 2010;10(10):1173-1184.
Heffernan M, et al. “The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.” Endocrinology. 2001;142(12):5182-5189.
Lee C, et al. “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.” Cell Metabolism. 2015;21(3):443-454.
Eremin KO, et al. “Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents.” Neurochemical Research. 2005;30(12):1493-1500.
NutraIngredients. “Investigation Finds Contamination in Grey-Market Research Peptides.” December 2025.
AllAboutPeptides. “Peptide Sciences Pulls the Plug: Major Research Supplier Abruptly Shuts Down.” March 2026.
FDA. “Bulk Drug Substances Used in Compounding.” fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding. Accessed March 2026.
Alliance for Pharmacy Compounding. “FDA Releases Final Interim Guidance on Bulk Drug Substances.” a4pc.org. January 2025.